tiprankstipranks
Revolution Medicines (RVMD)
NASDAQ:RVMD
US Market
RVMD
Revolution Medicines
RESEARCH TOOLSreports
Want to see RVMD full AI Analyst Report?

Revolution Medicines (RVMD) Stock Forecast & Price Target

727 Followers
See the Price Targets and Ratings of:

RVMD Analyst Ratings

Strong Buy
19Ratings
Strong Buy
19 Buy
0 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Revolution
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RVMD Stock 12 Month Forecast

Average Price Target

$172.41
▲(16.00% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $172.41 with a high forecast of $263.00 and a low forecast of $120.00. The average price target represents a 16.00% change from the last price of $148.63.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","90":"$90","148":"$148","206":"$206","264":"$264"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":263,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$263.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":172.41176470588235,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$172.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$120.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,90,148,206,264],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.64,111.28307692307692,123.92615384615385,136.56923076923078,149.2123076923077,161.85538461538462,174.49846153846153,187.14153846153846,199.7846153846154,212.42769230769233,225.07076923076926,237.7138461538462,250.35692307692307,{"y":263,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.64,104.31475113122173,109.98950226244344,115.66425339366516,121.33900452488687,127.0137556561086,132.6885067873303,138.36325791855205,144.03800904977376,149.71276018099547,155.38751131221719,161.0622624434389,166.73701357466064,{"y":172.41176470588235,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.64,100.28307692307692,101.92615384615385,103.56923076923077,105.21230769230769,106.85538461538462,108.49846153846154,110.14153846153846,111.78461538461539,113.42769230769231,115.07076923076923,116.71384615384616,118.35692307692308,{"y":120,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$263.00Average Price Target$172.41Lowest Price Target$120.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on RVMD
Leonid Timashev
RBC Capital
RBC Capital
$140→$162
Buy
9.00%
Upside
Reiterated
04/27/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Revolution Medicines (NASDAQ: RVMD) and Erasca (NASDAQ: ERAS)
LifeSci Capital Analyst forecast on RVMD
Charles Zhu
LifeSci Capital
LifeSci Capital
$185→$263
Buy
76.95%
Upside
Assigned
04/25/26
Buy Rating on RVMD Driven by Promising Pancreatic Cancer Data and Next‑Generation RAS Franchise Potential
Mizuho Securities Analyst forecast on RVMD
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$140→$185
Buy
24.47%
Upside
Reiterated
04/24/26
Mizuho Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)
Stifel Nicolaus Analyst forecast on RVMD
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$215
Buy
44.65%
Upside
Reiterated
04/23/26
Stifel Nicolaus Remains a Buy on Revolution Medicines (RVMD)
H.C. Wainwright Analyst forecast on RVMD
Robert Burns
H.C. Wainwright
H.C. Wainwright
$169
Buy
13.71%
Upside
Reiterated
04/22/26
Revolution Medicines: Daraxonrasib Data De‑Risk Pivotal Pancreatic Cancer Program, Supporting Buy Rating and $169 Target
Guggenheim Analyst forecast on RVMD
Michael Morris
Guggenheim
Guggenheim
$175
Buy
17.74%
Upside
Reiterated
04/22/26
Guggenheim Remains a Buy on Revolution Medicines (RVMD)
Bank of America Securities Analyst forecast on RVMD
Alec Stranahan
Bank of America Securities
Bank of America Securities
$170
Buy
14.38%
Upside
Reiterated
04/21/26
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), Revolution Medicines (RVMD)
Needham Analyst forecast on RVMD
Ami Fadia
Needham
Needham
$145→$186
Buy
25.14%
Upside
Assigned
04/20/26
Revolution Medicines: Strong Zoldonrasib Efficacy and Strengthened Balance Sheet Support Buy Rating and Higher Target
TD Cowen Analyst forecast on RVMD
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE) and Revolution Medicines (NASDAQ: RVMD)
J.P. Morgan Analyst forecast on RVMD
Brian Cheng
J.P. Morgan
J.P. Morgan
$175
Buy
17.74%
Upside
Reiterated
04/19/26
Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR) and Revolution Medicines (NASDAQ: RVMD)
Evercore ISI Analyst forecast on RVMD
Cory Kasimov
Evercore ISI
Evercore ISI
$140→$200
Buy
34.56%
Upside
Reiterated
04/14/26
Revolution Medicines price target raised to $200 from $140 at Evercore ISIRevolution Medicines price target raised to $200 from $140 at Evercore ISI
Wells Fargo Analyst forecast on RVMD
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$144→$167
Buy
12.36%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA) and Ligand Pharma (NASDAQ: LGND)
Wedbush Analyst forecast on RVMD
Robert Driscoll
Wedbush
Wedbush
$147
Buy
-1.10%
Downside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Insight Molecular Diagnostics (NASDAQ: IMDX), Revolution Medicines (NASDAQ: RVMD) and Travere Therapeutics (NASDAQ: TVTX)
Oppenheimer Analyst forecast on RVMD
Jay Olson
Oppenheimer
Oppenheimer
$150→$165
Buy
11.01%
Upside
Reiterated
04/13/26
Revolution Medicines price target raised to $165 from $150 at OppenheimerRevolution Medicines price target raised to $165 from $150 at Oppenheimer
Leerink Partners Analyst forecast on RVMD
Jonathan Chang
Leerink Partners
Leerink Partners
$115→$147
Buy
-1.10%
Downside
Reiterated
04/13/26
Revolution Medicines price target raised to $147 from $115 at LeerinkRevolution Medicines price target raised to $147 from $115 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on RVMD
Leonid Timashev
RBC Capital
RBC Capital
$140→$162
Buy
9.00%
Upside
Reiterated
04/27/26
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (NASDAQ: LGND), Revolution Medicines (NASDAQ: RVMD) and Erasca (NASDAQ: ERAS)
LifeSci Capital Analyst forecast on RVMD
Charles Zhu
LifeSci Capital
LifeSci Capital
$185→$263
Buy
76.95%
Upside
Assigned
04/25/26
Buy Rating on RVMD Driven by Promising Pancreatic Cancer Data and Next‑Generation RAS Franchise Potential
Mizuho Securities Analyst forecast on RVMD
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$140→$185
Buy
24.47%
Upside
Reiterated
04/24/26
Mizuho Securities Keeps Their Buy Rating on Revolution Medicines (RVMD)
Stifel Nicolaus Analyst forecast on RVMD
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$215
Buy
44.65%
Upside
Reiterated
04/23/26
Stifel Nicolaus Remains a Buy on Revolution Medicines (RVMD)
H.C. Wainwright Analyst forecast on RVMD
Robert Burns
H.C. Wainwright
H.C. Wainwright
$169
Buy
13.71%
Upside
Reiterated
04/22/26
Revolution Medicines: Daraxonrasib Data De‑Risk Pivotal Pancreatic Cancer Program, Supporting Buy Rating and $169 Target
Guggenheim Analyst forecast on RVMD
Michael Morris
Guggenheim
Guggenheim
$175
Buy
17.74%
Upside
Reiterated
04/22/26
Guggenheim Remains a Buy on Revolution Medicines (RVMD)
Bank of America Securities Analyst forecast on RVMD
Alec Stranahan
Bank of America Securities
Bank of America Securities
$170
Buy
14.38%
Upside
Reiterated
04/21/26
Analysts Are Bullish on These Healthcare Stocks: Cardiff Oncology (CRDF), Revolution Medicines (RVMD)
Needham Analyst forecast on RVMD
Ami Fadia
Needham
Needham
$145→$186
Buy
25.14%
Upside
Assigned
04/20/26
Revolution Medicines: Strong Zoldonrasib Efficacy and Strengthened Balance Sheet Support Buy Rating and Higher Target
TD Cowen Analyst forecast on RVMD
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/20/26
Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE) and Revolution Medicines (NASDAQ: RVMD)
J.P. Morgan Analyst forecast on RVMD
Brian Cheng
J.P. Morgan
J.P. Morgan
$175
Buy
17.74%
Upside
Reiterated
04/19/26
Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR) and Revolution Medicines (NASDAQ: RVMD)
Evercore ISI Analyst forecast on RVMD
Cory Kasimov
Evercore ISI
Evercore ISI
$140→$200
Buy
34.56%
Upside
Reiterated
04/14/26
Revolution Medicines price target raised to $200 from $140 at Evercore ISIRevolution Medicines price target raised to $200 from $140 at Evercore ISI
Wells Fargo Analyst forecast on RVMD
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$144→$167
Buy
12.36%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), IDEAYA Biosciences (NASDAQ: IDYA) and Ligand Pharma (NASDAQ: LGND)
Wedbush Analyst forecast on RVMD
Robert Driscoll
Wedbush
Wedbush
$147
Buy
-1.10%
Downside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Insight Molecular Diagnostics (NASDAQ: IMDX), Revolution Medicines (NASDAQ: RVMD) and Travere Therapeutics (NASDAQ: TVTX)
Oppenheimer Analyst forecast on RVMD
Jay Olson
Oppenheimer
Oppenheimer
$150→$165
Buy
11.01%
Upside
Reiterated
04/13/26
Revolution Medicines price target raised to $165 from $150 at OppenheimerRevolution Medicines price target raised to $165 from $150 at Oppenheimer
Leerink Partners Analyst forecast on RVMD
Jonathan Chang
Leerink Partners
Leerink Partners
$115→$147
Buy
-1.10%
Downside
Reiterated
04/13/26
Revolution Medicines price target raised to $147 from $115 at LeerinkRevolution Medicines price target raised to $147 from $115 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

3 Months
xxx
Success Rate
9/11 ratings generated profit
82%
Average Return
+25.16%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +25.16% per trade.
1 Year
Robert DriscollWedbush
Success Rate
14/17 ratings generated profit
82%
Average Return
+82.08%
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +82.08% per trade.
2 Years
xxx
Success Rate
13/13 ratings generated profit
100%
Average Return
+213.82%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +213.82% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVMD Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
7
6
5
7
7
Buy
36
43
45
47
53
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
49
50
54
60
In the current month, RVMD has received 60 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the past 3 months is 172.41.
Each month's total comprises the sum of three months' worth of ratings.

RVMD Financial Forecast

RVMD Earnings Forecast

Next quarter’s earnings estimate for RVMD is -$1.84 with a range of -$1.96 to -$1.61. The previous quarter’s EPS was -$1.86. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.
Next quarter’s earnings estimate for RVMD is -$1.84 with a range of -$1.96 to -$1.61. The previous quarter’s EPS was -$1.86. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.

RVMD Sales Forecast

Next quarter’s sales forecast for RVMD is $2.42M with a range of $0.00 to $20.80M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.
Next quarter’s sales forecast for RVMD is $2.42M with a range of $0.00 to $20.80M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.

RVMD Stock Forecast FAQ

What is RVMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Revolution Medicines’s 12-month average price target is 172.41.
    What is RVMD’s upside potential, based on the analysts’ average price target?
    Revolution Medicines has 16.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RVMD a Buy, Sell or Hold?
          Revolution Medicines has a consensus rating of Strong Buy which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Revolution Medicines’s price target?
            The average price target for Revolution Medicines is 172.41. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $263.00 ,the lowest forecast is $120.00. The average price target represents 16.00% Increase from the current price of $148.63.
              What do analysts say about Revolution Medicines?
              Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of RVMD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.